Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: A randomized controlled study

Abdulsalim, Suhaj; Unnikrishnan, Mazhuvancherry Kesavan; Manu, Mohan K; Alrasheedy, Alian A.; Godman, Brian; Morisky, Donald E.

doi:10.1016/j.sapharm.2017.10.008

Cited by 68 publications

(106 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, documentation also increased medication adherence in patients with COPD. 12 To enhance the productivity of their work, pharmacists should document the interventions provided to the patients. The documentation system should be a permanent medication record with rationale for providing the medication.…”

Section: Introductionmentioning

confidence: 99%

Pharmacist Intervention Documentation in Saudi Arabia

Alomi¹,

Badawoud²,

Al-Dosari³

et al. 2020

PTB Reports

View full text Add to dashboard Cite

Objectives: To explore the pharmacist intervention documentation in the Kingdom of Saudi Arabia. Methods: This is a 4-month cross-sectional self-administrated survey on documentation of pharmacist intervention. The study consisted of two parts: the first part collected demographic information and the second part comprised of a questionnaire with 18 questions. The second part included policy and procedure, type of data through pharmacist intervention, reporting workload of pharmacist intervention documentation. All types of pharmacist professionals were included in this survey. We used a 5-point Likert response scale system to obtain the responses. There were open-and close-ended questions. The survey was distributed through the social media (WhatsApp) and other social media to more than 1000 pharmacist professionals in the Kingdom of Saudi Arabia. The survey was distributed in an electronic format and the data were analyzed through Survey Monkey system. Results: A total of 128 pharmacists responded to the survey. Of them, 106 (82.81%) were Saudi and 22 (17.19%) were non-Saudi professionals. The majority of the responders were in the age group of 25-34 years and 35-44 years (44.53% and 25.00%, respectively). Most of the responders had obtained Bachelor of Pharmacy (40 (31.25%)) and Doctor of Pharmacy degree (33 (25.78%)) and the majority of the pharmacists (112 (87.50%)) were not accredited by the Board of Pharmaceutical Specialty. The average score of the administration element of pharmacist intervention documentation was 3.68 (73.66%). Policies and procedures of pharmacist intervention documentation obtained the highest score (4.13 (82.6%)) followed by the quality management (3.78 (75.60%)) and education with training (3.76 (75.20%)). Adverse drug reactions (92.86%) and medication errors (91.19%) were most of the recorded type of documentation and poisoning information inquiries (65.62%) and medication reconciliation (80.31%) were the least type of documentation, with an average 54.66% documented electronically. Conclusion: The pharmacist intervention documentation was found to be acceptable in the Kingdom of Saudi Arabia. The half of pharmacist intervention documentations was an electronic only. In the future, we recommend to improve the system and correct barriers related issues. This will enhance the process of documentation and explore the impact and role of the pharmacist in the Kingdom of Saudi Arabia.

show abstract

Section: Introductionmentioning

confidence: 99%

Pharmacist Intervention Documentation in Saudi Arabia

Alomi¹,

Badawoud²,

Al-Dosari³

et al. 2020

PTB Reports

View full text Add to dashboard Cite

show abstract

“…Pharmacists can help with medication management strategies as well as assist with addressing barriers to the use of, and adherence with, prescribed inhalers. Consequently, community pharmacists can potentially help reduce the morbidity, mortality and costs associated with COPD and delay its progression [44][45][46][47]. This is particularly important in India, given concerns with the number of physicians, especially in rural areas, due to a variety of issues [48][49][50].…”

Section: Introductionmentioning

confidence: 99%

“…As a result, counselling of COPD patients in terms of prevention strategies and inhaler techniques, as well as the use of spirometry for diagnosis, is typically limited [51]. This is a concern given the high levels of co-payment in India, which can have a devastating effect on families [8,52,53], as well as the current high burden of COPD in India [2,6,13]. Consequently, effective strategies are needed to address this, including the improved use of medicines to reduce subsequent co-payments [22].…”

Section: Introductionmentioning

confidence: 99%

“…Consequently, effective strategies are needed to address this, including the improved use of medicines to reduce subsequent co-payments [22]. We and others have shown that structured pharmacist-led interventions can improve the care of patients with COPD and help reduce costs [46,[54][55][56][57][58]. This is important, with the role of non-physician healthcare professionals growing in India to compensate for the lack of physicians [59].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India

Abdulsalim

Unnikrishnan

Manu

et al. 2019

PharmacoEconomics Open

Self Cite

View full text Add to dashboard Cite

Background Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality, especially in lowand middle-income countries (LMICs) such as India. Medicine costs are a key issue in LMICs, with typically high patient co-payments. In addition, pharmacists are underutilised in LMICs, including India. However, pharmacist-led educational interventions may improve the care of patients with COPD, as well as reduce medicine costs. Consequently, the objective of this study was to assess the effectiveness of a pharmacist-led intervention in reducing medicine costs. Methodology We assessed the impact of a pharmacist intervention on direct medicine costs in COPD patients (medicine costs and pharmacist time) in a randomised controlled study involving an intervention and control group, conducted at a tertiary care teaching hospital in India. Results The 6-monthly cost of medicines at baseline increased with disease severity, from a maximum of US$29.46 for those with mild COPD to US$63.28 for those with very severe COPD. Substantial savings in medical costs were achieved with the pharmacist-led programme, to a maximum of US$20.49 over 6 months for very severe patients. This equates to a reduction of 30.6% in medicine costs (p < 0.001), reduced to 26.1% when pharmacists' time (US$3.00/patient) was included. Conclusion There could be a key role for pharmacists as educators for COPD patients in LMICs, to improve care and reduce costs, including patient co-payments.

show abstract

“…Patient education programs improve patientsí health awareness and knowledge, symptom management, self-care practices and overall health status (10)(11)(12) thereby reducing the propensity for negative outcomes and associated treatment costs (13,14). Similar programs designed for patients with COPD have been implemented, especially around exacerbations (15)(16)(17), in community pharmacy settings (18)(19), or during rehabilitation (20,21). In recent years there have been studies that have looked at the impact of patient education programs on QoL or adherence or both (22)(23)(24)(25)(26) in patients with COPD.…”

mentioning

confidence: 99%

Impact of education on dimensions of adherence in patients with chronic obstructive pulmonary disease

Olah

Kresznerits

Gonda

et al. 2020

Acta Poloniae Pharmaceutica - Drug Research

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a severe respiratory disorder that poses a tremendous burden on healthcare and economic resources. The prevalence of COPD has been steadily rising globally (1) and COPD-associated mortality is predicted to be the third-leading cause of death by 2020 (2). While smoking is one of the major risk factors for developing COPD, other triggers include age, genetic predisposition, and history of bronchial asthma and recurrent respiratory infections (3). Age and COPD prevalence appears to have a positive correlation and approximately 9.0-10.0% of the >40-years population presents with COPD (4). The main goal of COPD management is to maintain stable lung function and prevent acute exacerbations. The pharmacotherapy of COPD includes bronchodilators such as fl2-adrenergic agonists (BAs) and muscarinic antagonists (MAs), and inhaled corticosteroids (5). The preferred route of administration of these agents is via the inhalation due to its advantages GENERAL

show abstract

Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: A randomized controlled study

Cited by 68 publications

References 43 publications

Pharmacist Intervention Documentation in Saudi Arabia

Pharmacist Intervention Documentation in Saudi Arabia

Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India

Impact of education on dimensions of adherence in patients with chronic obstructive pulmonary disease

Contact Info

Product

Resources

About